Edwards Lifesciences (EW) stock has drawn fresh attention as investors review its recent performance and financial profile, including a last close of $86.28 and full year revenue of $6,303.5 million.
See our latest analysis for Edwards Lifesciences.
Over the past year, Edwards Lifesciences has paired a 15.32% total shareholder return with steady short term momentum, including a 6.02% 1 month share price return and a 2.39% 3 month share price return. This performance suggests gradually improving sentiment around its cardiovascular portfolio.
If you are comparing Edwards Lifesciences to other healthcare related opportunities, this could be a good moment to scan for specialised growth stories in 39 healthcare AI stocks
With Edwards Lifesciences showing full year revenue of $6,303.5 million, net income of $1,075.6 million and a recent close of $86.28, the key question is whether the current valuation leaves upside on the table or if markets are already pricing in future growth.
Most Popular Narrative: 11% Undervalued
On the most followed narrative, Edwards Lifesciences stock at $86.28 sits below an implied fair value of $96.92, which hinges on specific growth and margin assumptions.
The expected approval of the early TAVR indication in the second quarter, along with policy and guideline changes in the U.S. and globally, represents a multiyear growth opportunity that could significantly enhance revenue streams in the future. The planned launch of the transcatheter tricuspid valve EVOQUE in 2024 is anticipated to uniquely position Edwards to gain market share and increase revenues as it becomes the first company to develop and offer this therapy.
Curious what revenue trajectory, margin lift and future earnings multiple are baked into that fair value, and how they connect back to those valve therapies and new indications.
Result: Fair Value of $96.92 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, the Edwards Lifesciences narrative could be pressured if tariffs weigh more heavily on margins or if competition limits the expected growth in TAVR procedures.
Find out about the key risks to this Edwards Lifesciences narrative.
Another View: Edwards Lifesciences Stock Through Earnings Multiples
While the Edwards Lifesciences fair value of $96.92 points to an 11% gap versus the $86.28 share price, the current P/E of 46.2x tells a different story. It sits well above the US Medical Equipment industry at 24.5x, the peer average at 25.1x, and the fair ratio of 28.8x, which all signal that the market is already paying a high price for each dollar of earnings. For investors, the question is whether that premium reflects durable growth or instead leaves less room if expectations are challenged.
See what the numbers say about this price — find out in our valuation breakdown.
Next Steps
With mixed signals on valuation and expectations hanging on Edwards Lifesciences, it helps to weigh both the concerns and the upside before reacting. To see how these cross currents balance out, review the 2 key rewards and 3 important warning signs
Looking for more investment ideas beyond Edwards Lifesciences?
Do not stop with Edwards Lifesciences. Broaden your watchlist by scanning focused stock ideas that match the way you like to balance risk, return and quality.
- Spot potential bargains early by reviewing companies flagged in the screener containing 20 high quality undiscovered gems
- Prioritise resilience by concentrating on businesses highlighted in the 68 resilient stocks with low risk scores
- Strengthen your portfolio core by focusing on companies featured in the solid balance sheet and fundamentals stocks screener (48 results)
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com